Roche's Hemlibra treatment for haemophilia A is one of its top-selling drugs, making almost $5 billion last year, and the company has now lined up what looks like an impressive successor. The pharma ...
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close. In January 2025, Axsome added a third product to its lineup with the U.S. Food and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results